Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

276 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Low glycemic index diet, exercise and vitamin D to reduce breast cancer recurrence (DEDiCa): design of a clinical trial.
Augustin LS, Libra M, Crispo A, Grimaldi M, De Laurentiis M, Rinaldo M, D'Aiuto M, Catalano F, Banna G, Ferrau' F, Rossello R, Serraino D, Bidoli E, Massarut S, Thomas G, Gatti D, Cavalcanti E, Pinto M, Riccardi G, Vidgen E, Kendall CW, Jenkins DJ, Ciliberto G, Montella M. Augustin LS, et al. Among authors: de laurentiis m. BMC Cancer. 2017 Jan 23;17(1):69. doi: 10.1186/s12885-017-3064-4. BMC Cancer. 2017. PMID: 28114909 Free PMC article.
Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments.
Del Mastro L, Fabi A, Mansutti M, De Laurentiis M, Durando A, Merlo DF, Bruzzi P, La Torre I, Ceccarelli M, Kazeem G, Marchi P, Boy D, Venturini M, De Placido S, Cognetti F. Del Mastro L, et al. Among authors: de placido s, de laurentiis m. BMC Cancer. 2013 Mar 28;13:164. doi: 10.1186/1471-2407-13-164. BMC Cancer. 2013. PMID: 23537313 Free PMC article. Clinical Trial.
Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial.
Lambertini M, Poggio F, Bruzzone M, Conte B, Bighin C, de Azambuja E, Giuliano M, De Laurentiis M, Cognetti F, Fabi A, Bisagni G, Durando A, Turletti A, Urracci Y, Garrone O, Puglisi F, Montemurro F, Ceppi M, Del Mastro L; GIM2 investigators. Lambertini M, et al. Among authors: de azambuja e, de laurentiis m. Int J Cancer. 2020 Jul 1;147(1):160-169. doi: 10.1002/ijc.32789. Epub 2019 Dec 4. Int J Cancer. 2020. PMID: 31724170
Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials.
De Laurentiis M, Cancello G, D'Agostino D, Giuliano M, Giordano A, Montagna E, Lauria R, Forestieri V, Esposito A, Silvestro L, Pennacchio R, Criscitiello C, Montanino A, Limite G, Bianco AR, De Placido S. De Laurentiis M, et al. Among authors: de placido s. J Clin Oncol. 2008 Jan 1;26(1):44-53. doi: 10.1200/JCO.2007.11.3787. J Clin Oncol. 2008. PMID: 18165639
Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.
von Minckwitz G, Puglisi F, Cortes J, Vrdoljak E, Marschner N, Zielinski C, Villanueva C, Romieu G, Lang I, Ciruelos E, De Laurentiis M, Veyret C, de Ducla S, Freudensprung U, Srock S, Gligorov J. von Minckwitz G, et al. Among authors: de ducla s, de laurentiis m. Lancet Oncol. 2014 Oct;15(11):1269-78. doi: 10.1016/S1470-2045(14)70439-5. Epub 2014 Sep 28. Lancet Oncol. 2014. PMID: 25273342 Clinical Trial.
Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time?
Buono G, Gerratana L, Bulfoni M, Provinciali N, Basile D, Giuliano M, Corvaja C, Arpino G, Del Mastro L, De Placido S, De Laurentiis M, Cristofanilli M, Puglisi F. Buono G, et al. Among authors: de placido s, de laurentiis m. Cancer Treat Rev. 2019 Feb;73:73-83. doi: 10.1016/j.ctrv.2019.01.004. Epub 2019 Jan 11. Cancer Treat Rev. 2019. PMID: 30682661 Free article. Review.
Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests.
Saponaro M, Annunziata L, Turla A, Viganò I, De Laurentiis M, Giuliano M, Del Mastro L, Montemurro F, Puglisi F, De Angelis C, Buono G, Schettini F, Arpino G. Saponaro M, et al. Among authors: de angelis c, de laurentiis m. Int J Mol Sci. 2022 Nov 6;23(21):13604. doi: 10.3390/ijms232113604. Int J Mol Sci. 2022. PMID: 36362392 Free PMC article. Review.
A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer.
De Laurentiis M, Arpino G, Massarelli E, Ruggiero A, Carlomagno C, Ciardiello F, Tortora G, D'Agostino D, Caputo F, Cancello G, Montagna E, Malorni L, Zinno L, Lauria R, Bianco AR, De Placido S. De Laurentiis M, et al. Among authors: de placido s. Clin Cancer Res. 2005 Jul 1;11(13):4741-8. doi: 10.1158/1078-0432.CCR-04-2569. Clin Cancer Res. 2005. PMID: 16000569 Free article.
276 results